BioSpace News Archive

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total.

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in-human clinical trial.

BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) has appointed renowned astronaut Chris Hadfield to its board of advisors as part of a drive to leverage its biotech technology platform.

Gelesis, a consumer-focused biotherapeutics company, is proud to announce Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults who meet the prescription criteria.

2seventy bio, Inc . (Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30, 2021.

Fluidx Medical Technology today announced the oversubscribed closing of the first tranche of its Series A financing round.

Rallybio Corporation today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo.

Labcorp today announced a collaboration to optimize precision oncology research.

Alimera Sciences, Inc. today announces the addition of Erin Parsons to its Board of Directors.

Arch Biopartners Inc. announced today that its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) will enter the Canadian Treatments for COVID-19.